Chronic Cough Concerns (AAN)

Price: FREE for members and non-members

Session recorded on November 17, 2022
Speaker: J. Wesley Sublett, MD

Description: The etiology and management of chronic cough is challenging for both patient and provider due to the wide differential and/or multifactorial nature. Understanding the mechanisms that lead to cough is paramount. Cough hypersensitivity syndrome that does not respond to asthma, rhinitis and/or GERD therapy is an emerging area of interest.

Viewers can earn credit by completing the posttest questions.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers

Learning Objectives

Upon completion of this activity learners should be able to:

1. Understand the pathogenesis and mechanism of chronic cough
2. Evaluate and treat a patient with chronic cough
3. Explain therapeutic agents in the treatment of cough

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
Course expires: 

All relevant finaicial relationships have been mitigated.

Michael Blaiss, MD, FACAAI Planner
Disclosures: Consultant: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare

J. Wesley Sublett, MD, Speaker
Aimmune Independent Contractor; ALK: Independent Contractor; AstraZeneca: Advisor, Speaker, Independent Contractor; BioCryst: Independent Contractor, Researcher; Evidera: Independent Contractor, Researcher; GlaxoSmithKline: Independent Contractor, Researcher; LEO: Independent Contractor, Researcher; Novartis: Independent Contractor, Researcher; Octapharma: Independent Contractor, Researcher; Regeneron: Advisor, Speaker, Independent Contractor, Researcher; Sanofi: Advisor, Speaker, Independent Contractor, Researcher; TEVA: Independent Contractor, Researcher; Byrn Pharma: Advisor; Pfizer: Advisor, Speaker; Optinose: Advisor; Bellus: Advisor


Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.